Taltz (ixekizumab) is a biologic monoclonal antibody that was approved by the FDA in 2016 for plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. As of now, there are no biosimilars of ixekizumab that have been approved for use in the United States or elsewhere.
Why no biosimilars yet?
| Factor | Impact on biosimilar development |
|--------|---------------------------------|
| Patent and exclusivity | Ixekizumab’s patents (both formulation and process) and regulatory exclusivity periods make it difficult for other companies to develop a biosimilar without infringing on intellectual property. |
| Manufacturing complexity | Monoclonal antibodies are produced in living cell cultures, which require highly controlled manufacturing processes. Even small deviations can affect the drug’s safety and efficacy, raising the bar for biosimilar approval. |
| Market dynamics | The market for psoriasis and psoriatic arthritis therapies is dominated by several established biologics. New entrants often focus on more cost‑effective or differentiated products. |
What’s happening in the market?
- Competitive landscape: Companies like AbbVie (Humira), Pfizer (Enbrel), and Janssen (Remicade) already have a strong foothold in the psoriasis/arthritis space, and they have their own biosimilar programs. For ixekizumab, the focus is still on expanding indications and optimizing dosing regimens rather than pursuing a biosimilar.
- Regulatory pathways: If a company were to develop a biosimilar for ixekizumab, it would need to undergo the rigorous FDA biosimilar approval pathway, demonstrating that it is “highly similar” to the reference product with no clinically meaningful differences in safety, purity, and potency.
- Patent status: The main patents covering ixekizumab’s structure and manufacturing are expected to expire in the next decade, after which competitors could start pursuing biosimilar development.
Bottom line
No biosimilars for Taltz are currently approved. If you’re interested in alternative treatments or cost‑effective options, it might be worth discussing other biologics (e.g., adalimumab, secukinumab) or newer therapies that have biosimilar competitors with your healthcare provider.